Zaki Mohamed 4

What Happened

• Zaki Mohamed, Chief Medical Officer of ADC Therapeutics (ADCT), was awarded 285,200 common shares (restricted share units) on 2026-02-13 at a reported value/price of $3.99/share (total value $1,137,948). On the same date the issuer withheld 24,603 shares at $3.99/share (value $98,166) to satisfy the reporting person’s tax withholding obligations related to previously vested RSUs. The 285,200-share award vests one-third on each anniversary starting Feb 13, 2027 (per filing footnote).

Key Details

• Transaction dates and prices:
  • 2026-02-13 — Award (code A): 285,200 shares @ $3.99 = $1,137,948 (RSU grant)
  • 2026-02-13 — Tax withholding (code F): 24,603 shares @ $3.99 = $98,166 (shares withheld/ disposed to cover taxes)
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnotes:
  • F1: Awarded RSUs settle as common shares and vest 1/3 on each anniversary beginning Feb 13, 2027, subject to continued service.
  • F2: The withheld 24,603 shares were retained by the issuer to satisfy tax withholding on vested RSUs previously granted.
• Filing timeliness: Form 4 filed 2026-02-18 for a 2026-02-13 transaction — appears filed within the required reporting window (timely).

Context

• These transactions are RSU awards and corporate tax-withholding actions, not open-market purchases or sales. The award itself is compensation (not a buy signal); the withheld shares represent a tax settlement rather than a discretionary sale.